Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CART123 in Relapsed/Refractory AML
NCT03766126Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Dec 2018
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART123 in acute myeloid leukemia (AML) (3 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Safety profile of CART123 cells by monitoring the frequency and severity of adverse events at 15 years and Percentage of manufacturing products that do not meet release criteria at 1 year. Started Dec 2018; status: terminated.
02
Drugs
CART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03766126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766126.